Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123801 | 1.00 | GAA (0.46) | GAASLC22A1CYP3A4CYP2D6TSHR | |
| SCHEMBL12646370 | 1.00 | GAA (0.46) | GAASLC22A1CYP3A4CYP2D6TSHR | |
| SCHEMBL12588899 | 0.87 | GAA (0.35) | GAASLC22A1CYP3A4CYP2D6TSHR | |
| SCHEMBL6123701 | 0.84 | SLC22A1 (0.38) | GAASLC22A1CYP3A4CYP2D6TSHR | |
| SCHEMBL13301276 | 0.83 | GAA (0.32) | GAASLC22A1CYP3A4CYP2D6TSHR | |
| SCHEMBL10222582 | 0.81 | GAA (0.66) | GAASLC22A1CYP3A4CYP2D6TSHR | |
| SCHEMBL14768978 | 0.81 | GAA (0.66) | GAASLC22A1CYP3A4CYP2D6TSHR | |
| SCHEMBL21202053 | 0.80 | GAA (0.43) | GAATSHROPRM1OPRD1OPRK1 | |
| SCHEMBL10033224 | 0.77 | GAA (0.54) | GAACYP3A4CYP2D6LMNAOPRM1 | |
| SCHEMBL10066077 | 0.77 | GAA (0.54) | GAACYP3A4CYP2D6OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148528-B2 | Processes and compounds for the preparation of normorphinans | MALLINCKRODT LLC (US) | 2012-04-03 | — | — | US | disclosed |
| US-8115002-B2 | Preparation of substituted morphinan-6-ones and salts and intermediates thereof | MALLINCKRODT LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-8115002-B2 | Preparation of substituted morphinan-6-ones and salts and intermediates thereof | MALLINCKRODT LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2099764-B1 | PREPARATION OF SUBSTITUTED MORPHINAN-6-ONES AND SALTS AND INTERMEDIATES THEREOF | MALLINCKRODT INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100048906-A1 | Preparation of Substituted Morphinan-6-Ones and Salts and Intermediates Thereof | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048906-A1 | Preparation of Substituted Morphinan-6-Ones and Salts and Intermediates Thereof | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-02-25 | — | — | US | disclosed |
| US-20090299069-A1 | Processes and Compounds for the Preparation of Normorphinans | MALLINCKRODT INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2008036172-A1 | PREPARATION OF SUBSTITUTED MORPHINAN-6-ONES AND SALTS AND INTERMEDIATES THEREOF | MALLINCKRODT INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299069-A1 | Processes and Compounds for the Preparation of Normorphinans | CRH, NPSR1, AVPR1B | GAA 1845/4885SLC22A1 4653/4885CYP3A4 1250/4885 |
| US-20100048906-A1 | Preparation of Substituted Morphinan-6-Ones and Salts and Intermediates Thereof | CYP2D6, RTN4, UGT1A6 | GAA 3206/4885SLC22A1 2890/4885CYP3A4 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.